Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Int J Immunopharmacol ; 14(5): 871-6, 1992 Jul.
Article in English | MEDLINE | ID: mdl-1387391

ABSTRACT

Polyclonal activation of lymphocytes and immune complex-mediated glomerular lesions were induced in C57Bl/6 mice by injecting bacterial lipopolysaccharide (LPS) twice a week for 2 weeks. The usefulness of such a model for in vivo evaluation of immunomodulatory and therapeutic effects of drugs, was investigated by treating mice with DIAM4, a cyclophosphazenic compound known to modulate polyclonal activation of lymphocytes and to prevent mouse lupus nephritis. Prevention of LPS-triggered lymphocyte polyclonal activation and glomerular lesions was observed in the DIAM4-treated mice. Such a model can be used conveniently to select compounds effective in the treatment of immune glomerulonephritis.


Subject(s)
Glomerulonephritis/prevention & control , Immune Complex Diseases/prevention & control , Animals , Antibodies, Antinuclear/analysis , Aziridines/therapeutic use , Complement C3/metabolism , Disease Models, Animal , Female , Glomerulonephritis/immunology , Immune Complex Diseases/immunology , Lipopolysaccharides/toxicity , Mice , Mice, Inbred C57BL , Organophosphorus Compounds/therapeutic use
2.
Anticancer Res ; 10(6): 1563-9, 1990.
Article in English | MEDLINE | ID: mdl-2285228

ABSTRACT

Since the polyamine metabolism system is very active in proliferative glioma cells, polyamine linked drugs are to be considered as potential antineoplastic agents against malignant gliomas. This study reports the trial of a new compound lineage, the Polyamine Linked Cyclophosphazenes, on human glioblastoma heterografts in nu-nu mice. Two agents are tested: DIAM 3 and DIAM 4. Both show an important antineoplastic action either on a chronic treatment schedule or as single dose. Systemic tolerance is satisfactory.


Subject(s)
Antineoplastic Agents/therapeutic use , Aziridines/therapeutic use , Diamines/therapeutic use , Glioma/drug therapy , Organophosphorus Compounds/therapeutic use , Animals , Carmustine/therapeutic use , Cell Line , Cisplatin/therapeutic use , Drug Evaluation, Preclinical , Glioma/pathology , Humans , Mice , Mice, Nude , Neoplasm Transplantation , Transplantation, Heterologous
4.
J Clin Lab Immunol ; 32(2): 85-90, 1990 Jun.
Article in English | MEDLINE | ID: mdl-1967044

ABSTRACT

MRL-lpr/lpr mice develop T cell lymphadenopathy, polyclonal activation of B lymphocytes, autoantibodies and lupus nephritis. B and T cell populations, the dysfunctions of which play a role in the pathophysiology of the mouse disease, represent potential targets for lupus treatment. MRL-lpr/lpr mice are treated from the age of 19 weeks, i.e. after the onset of renal disease and lymphoproliferation, with Cyclosporin A which acts at the T cell level, or with DIAM4 which can down modulate polyclonal activation of B lymphocytes. DIAM4 induces the disappearance of the lymphoproliferation, the increase in C3 levels and the decrease in anti-DNA antibody, immunoglobulin and urea levels, and proteinuria. Cyclosporin A reduces lymph node hyperplasia, but has no effect on other parameters of the disease.


Subject(s)
Aziridines/therapeutic use , Cyclosporine/therapeutic use , Immunosuppressive Agents/therapeutic use , Lupus Nephritis/drug therapy , Lymphoproliferative Disorders/drug therapy , Mice, Mutant Strains/immunology , Organophosphorus Compounds/therapeutic use , Age Factors , Albuminuria/drug therapy , Albuminuria/etiology , Animals , Antibody Formation/drug effects , Aziridines/pharmacology , Cyclosporine/pharmacology , Hypergammaglobulinemia/drug therapy , Hypergammaglobulinemia/genetics , Immunoglobulins/analysis , Immunosuppressive Agents/pharmacology , Lupus Nephritis/complications , Lupus Nephritis/genetics , Lymphoproliferative Disorders/genetics , Mice , Organophosphorus Compounds/pharmacology , Sodium Chloride/pharmacology , Structure-Activity Relationship
5.
Int J Immunopharmacol ; 12(5): 555-60, 1990.
Article in English | MEDLINE | ID: mdl-2210915

ABSTRACT

Cyclophosphazenic compounds bearing ethylene-imino groups are cytocydal chemicals which can modulate polyclonal activation of lymphocytes (PAL) and prevent the development of murine lupus. The effects on PAL of the different parts of these chemicals and of vectorization by polyamines have been investigated by treating lipopolysaccharide injected C57Bl/6 mice with various cyclophosphazenic compounds and thiotepa. The immune effects of the cyclophosphazenic substances have been found to be mediated by ethylene-imino groups and to be modulated by polyamine vectorization. These compounds might represent a new class of drugs for treatment of immune mediated diseases of the lupus type.


Subject(s)
Adjuvants, Immunologic/pharmacology , Aziridines/pharmacology , Imides/pharmacology , Lymphocyte Activation/drug effects , Organophosphorus Compounds/pharmacology , Animals , Dose-Response Relationship, Drug , Ethylenes/pharmacology , Female , Imino Acids/pharmacology , Mice , Polyamines/pharmacology , Structure-Activity Relationship
6.
Clin Exp Immunol ; 59(1): 169-76, 1985 Jan.
Article in English | MEDLINE | ID: mdl-3871676

ABSTRACT

The effects of a cyclophosphazene derived drug (SOAz), on the polyclonal activation of B lymphocytes induced by bacterial lipopolysaccharide (LPS) have been studied in C57B1/6 mice. It has been found that this drug is able to inhibit the polyclonal stimulation of lymphocytes and a dose-dependent effect has been observed. The therapeutic effects of SOAz injected five times a week at 40 mg/kg/day have been investigated in mice chronically injected with LPS (twice a week, 2.5 mg/kg/day) which developed an immune complex type of glomerulonephritis. A marked prevention of glomerular lesions and of deposits of IgM and IgG, and of the third complement component has been found in mice treated with SOAz as compared to not treated mice.


Subject(s)
Azirines/pharmacology , B-Lymphocytes/immunology , Glomerulonephritis/prevention & control , Lymphocyte Activation/drug effects , Animals , Antigen-Antibody Complex , Dose-Response Relationship, Immunologic , Female , Glomerulonephritis/immunology , Glomerulonephritis/pathology , Immunoglobulins/analysis , Kidney/pathology , Lipopolysaccharides , Mice , Mice, Inbred C57BL , Time Factors
7.
Biochem Pharmacol ; 33(17): 2749-53, 1984 Sep 01.
Article in English | MEDLINE | ID: mdl-6466382

ABSTRACT

Interactions of the antitumoral drug SOAz with natural and model membranes are described. Biological studies were carried out with the bacterium Streptococcus pneumoniae taken as a model system. They reveal that SOAz is able to reduce delta psi and the delta psi-dependent amino acid transports without being cytotoxic for the bacteria. With respect to model membranes, leakage studies carried out with Na+ and K+ loaded lipid vesicles demonstrated that SOAz exhibits no ionophore activity. In contrast, the drug is shown to decrease the surface potential of monolayers of acidic phospholipids but without penetrating within the film. The possibility that SOAz might alter the delta psi part of the proton motive force by decreasing the outside surface potential of the bacterial membrane is discussed.


Subject(s)
Amino Acids/metabolism , Antineoplastic Agents/pharmacology , Azirines/pharmacology , Biological Transport/drug effects , Dicyclohexylcarbodiimide/pharmacology , Isoleucine/metabolism , Membrane Potentials , Membranes, Artificial , Streptococcus pneumoniae/metabolism , Valinomycin/pharmacology
8.
Anticancer Res ; 4(1-2): 41-4, 1984.
Article in English | MEDLINE | ID: mdl-6712175

ABSTRACT

The influence of an antitumoral drug, the pentaziridinocyclodiphosphatiazene (SOAZ), on the right----left-handed helix conformational transition of Poly (dG-dC). Poly (dG-dC) induced by carcinogenic or mutagenic Nickel compounds has been studied by ultraviolet absorbance and circular dichroïsm measurements. The B----Z transition of the polynucleotide is induced in two steps, in a similar way whatever the origin of the Nickel ions (NiCl2, NiSO4, Ni3S2, NiCO3). The midpoint of the second step (right----left-transition) is located around 0.4 mM Ni2+. The addition of SOAZ to the Poly (dG-dC). Poly (dG-dC) modifies this transition which is shifted to 2 mM Ni2+ for a 1 SOAZ/10 DNA phosphates ratio. The right-handed helix is stabilized and for a 1.5 SOAZ/phosphate ratio no B----Z transition is observed even for a tenfold amount of added Nickel (4 mM Ni2+). The addition of SOAZ to the DNA initially converted to a Z conformation by the presence of Nickel inhibits the return to the B form.


Subject(s)
Antineoplastic Agents/pharmacology , Azirines/pharmacology , Carcinogens , DNA , Nickel/toxicity , Nucleic Acid Conformation , Circular Dichroism , Polydeoxyribonucleotides , Spectrophotometry, Ultraviolet
9.
IARC Sci Publ ; (53): 227-34, 1984.
Article in English | MEDLINE | ID: mdl-6532982

ABSTRACT

The B----Z conformational transition of double-stranded poly(dG-dC) induced by various nickel salts (chloride, sulfate, subsulfide, carbonate) has been studied by ultraviolet absorption and circular dichroism. The spectra of the nickel compounds, both free and complexed with DNA, have been obtained in the visible and near infrared regions. In all cases the nickel adopts the hexacoordinated ionic form [Ni(H2O6]2+ and induces the B----Z transition of the nucleic acid at submillimolar concentrations (typically 0.4 mM). The addition to the poly(dG-dC)-poly(dG-dC) of an antitumoral drug, pentaziridinocyclodiphosphathiazene (SOAz), inhibits the B----Z transition even at a ten-fold higher nickel concentration (4 mM). Possible implications for carcinogenesis are discussed.


Subject(s)
Carcinogens , DNA , Nickel , Polydeoxyribonucleotides , Antineoplastic Agents , Azirines , Chemical Phenomena , Chemistry , Circular Dichroism , Humans , Spectrophotometry, Ultraviolet
10.
Anticancer Res ; 3(6): 425-9, 1983.
Article in English | MEDLINE | ID: mdl-6230986

ABSTRACT

The antineoplastic activity of hexaziridinocyclotriphosphazene (Myko 63) has been investigated in a panel of murine ascitic and solid tumors. Myko 63 was found to significantly retard primary and secondary tumor growth and to prolong the survival rates in each of the nine models employed. These included the L1210 and P388 leukemias, P815 mastocytoma, the 3LL and Madison 109 carcinomas, M5076 reticulum cell sarcoma, the line 26 colon and line 16 mammary carcinomas, and an intracranially implanted ependymoblastoma. The possible modes of action of this compound and the potentials of cyclophosphazenes, a chemical class largely unexplored as antitumor agents are discussed.


Subject(s)
Antineoplastic Agents/therapeutic use , Aziridines/therapeutic use , Azirines/therapeutic use , Neoplasms, Experimental/drug therapy , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Leukemia, Experimental/drug therapy , Male , Mice , Mice, Inbred Strains
13.
Biomed Mass Spectrom ; 7(9): 405-9, 1980 Sep.
Article in English | MEDLINE | ID: mdl-6451244

ABSTRACT

Mass spectrometry has been used for testing the chemical purity of some new antitumor cyclophosphazene compounds. the spectrum of N3P3Az6 (code name MYKO 63)--which exhibits noticeable activity on murine P 388, L 1210 and B 16 tumors--appeared to be remarkably simple, as most of the fragmentations arose from successive losses of the aziridino radicals. Traces of the pentaziridinomonochloro impurity formed by an incomplete substitution of N3P3Cl6 chlorine atoms under aziridinolysis could be detected in an impure and toxic sample by spectral subtraction. Quantification of this impurity was performed by selected ion monitoring in the direct inlet mode of sample introduction. The mass spectra of other derivatives of this class of compounds are slightly more complex, since the decomposition pathways showed more intense H-transfers associated with the loss of substituents.


Subject(s)
Antineoplastic Agents/analysis , Aziridines/analysis , Azirines/analysis , Drug Contamination , Aziridines/analogs & derivatives , Chemical Phenomena , Chemistry , Mass Spectrometry
15.
Poumon Coeur ; 33(6): 345-50, 1977.
Article in French | MEDLINE | ID: mdl-611479

ABSTRACT

In 196 cases of gastro-oesophageal reflux, simple or connected to a hiatal hernia or to a cardio-tuberous misplacement, the respiratory signs that are found in 1 patient out of 4, are analyzed. The nocturnal fits of coughing (39 cases, 20% of the reflux) is the most frequent sign of laryngo-tracheal aspiration of stomach content. This symptom of great diagnostic value, though neglected, should be looked for systematically. Other troubles are less frequent: bouts of recurring broncho-pulmonary infections, asthma attack, Mendelson's syndrome, pulmonary fibrosis. In absence of a patent cause, the symptoms should lead to suspect a reflux of stomach content in the airways. Similarly to oesophagitis, respiratory signs represent a complication sometimes serious, of gastro-oesophageal reflux, needing more frequently a surgical treatment of hiatal herniae or of the cardiac inefficiency.


Subject(s)
Bronchial Diseases/etiology , Esophageal Achalasia/complications , Gastroesophageal Reflux/complications , Hernia, Diaphragmatic/complications , Lung Diseases/etiology , Adult , Aged , Asthma/etiology , Cough/etiology , Female , Humans , Male , Middle Aged , Posture
SELECTION OF CITATIONS
SEARCH DETAIL
...